[Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years]

Nihon Kokyuki Gakkai Zasshi. 2006 Sep;44(9):653-8.
[Article in Japanese]

Abstract

Case 1 is a 78-year-old woman in whom lung adenocarcinoma with multiple brain metastasis (cT2N3M1, stage IV) was diagnosed. She was treated with Gefitinib alone. Her lung tumor and metastatic brain lesions decreased 6 months after the start of therapy. She has no recurrence and is still alive with a good performance status after 25 months. Case 2 is an 80-year-old woman in whom lung adenocarcinoma with multiple brain (cT2N3M1, stage IV) was diagnosed. She was also treated with Gefitinib alone and her lung tumor and metastatic brain becomes improved 6 months after the start of therapy. She maintained a good performance status for more than 2 years (29 months). However, 29 months after beginning treatment, she had recurrence in bone and died 2 months later, 31 months after the start of therapy. The prognosis of non-small cell lung cancer with multiple brain metastasis is very poor and the efficacy of chemotherapy for the treatment of multiple brain metastases is limited, and longterm survival remains disappointing. We report two lung adenocarcinoma patients with multiple brain metastasis who survived more than 2 years by treatment with Gefitinib alone.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Papillary / drug therapy*
  • Adenocarcinoma, Papillary / secondary
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / secondary*
  • Drug Administration Schedule
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Quinazolines / therapeutic use*
  • Radiotherapy Dosage
  • Survivors

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Gefitinib